287 related articles for article (PubMed ID: 26818835)
1. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
[TBL] [Abstract][Full Text] [Related]
2. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
3. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
[TBL] [Abstract][Full Text] [Related]
4. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
Front Oncol; 2020; 10():950. PubMed ID: 32612954
[TBL] [Abstract][Full Text] [Related]
5. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
Zilenaite-Petrulaitiene D; Rasmusson A; Besusparis J; Valkiuniene RB; Augulis R; Laurinaviciene A; Plancoulaine B; Petkevicius L; Laurinavicius A
Virchows Arch; 2024 Jan; ():. PubMed ID: 38217716
[TBL] [Abstract][Full Text] [Related]
7. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
8. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue.
Laurinavicius A; Plancoulaine B; Laurinaviciene A; Herlin P; Meskauskas R; Baltrusaityte I; Besusparis J; Dasevicius D; Elie N; Iqbal Y; Bor C
Breast Cancer Res; 2014; 16(2):R35. PubMed ID: 24708745
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
Front Oncol; 2021; 11():774088. PubMed ID: 34858854
[TBL] [Abstract][Full Text] [Related]
12. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
13. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
17. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
18. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
19. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining.
Dessauvagie B; Thomas A; Thomas C; Robinson C; Combrink M; Budhavaram V; Kunjuraman B; Meehan K; Sterrett G; Harvey J
Pathology; 2019 Dec; 51(7):681-687. PubMed ID: 31630876
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
